Literature DB >> 20077527

Splenic marginal zone lymphoma: characterization of 7q deletion and its value in diagnosis.

A James Watkins1, Yuanxue Huang, Hongtao Ye, Estelle Chanudet, Nicola Johnson, Rifat Hamoudi, Hongxiang Liu, Gehong Dong, Ayoma Attygalle, Ellen D McPhail, Mark E Law, Peter G Isaacson, Laurence de Leval, Andrew Wotherspoon, Ming-Qing Du.   

Abstract

The diagnosis of splenic marginal zone lymphoma (SMZL) is frequently a challenge, due to its lack of specific histological features and immunophenotypic markers, and the existence of other poorly characterized splenic lymphomas defying classification. Moreover, the clinical outcome of SMZL is variable, with 30% of cases pursuing an aggressive clinical course, the prediction of which remains problematic. Thus, there is a real need for biomarkers in the diagnosis and prognostication of SMZL. To search for genetic markers, we comprehensively investigated the genomic profile, TP53 abnormalities, and immunoglobulin heavy gene (IGH) mutation in a large cohort of SMZLs. 1 Mb resolution array comparative genomic hybridization (aCGH) on 25 SMZLs identified 7q32 deletion (44%) as the most frequent copy number change, followed by gains of 3q (32%), 8q (20%), 9q34 (20%), 12q23-24 (8%), and chromosome 18 (12%), and losses of 6q (16%), 8p (12%), and 17p (8%). High-resolution chromosome 7 tile-path aCGH on 17 SMZLs with 7q32 deletion identified by 1 Mb aCGH or interphase FISH screening mapped the minimal common deletion to a 3 Mb region at 7q32.1-32.2. Although it is not yet possible to identify the genes targeted by the deletion, interphase FISH screening showed that the deletion was seen in SMZL (19/56 = 34%) and splenic B-cell lymphoma/leukaemia unclassifiable (3/9 = 33%), but not in 39 cases of other splenic lymphomas including chronic lymphocytic leukaemia (n = 14), hairy cell leukaemia (4), mantle cell lymphoma (12), follicular lymphoma (6), and others. In SMZL, 7q32 deletion was inversely correlated with trisomy 18, but not associated with other copy number changes, TP53 abnormalities, or IGH mutation status. None of the genetic parameters examined showed significant and independent association with overall or event-free survival. In conclusion, 7q32 deletion is a characteristic feature of SMZL, albeit seen in isolated cases of splenic B-cell lymphoma/leukaemia unclassifiable, and its detection may help the differential diagnosis of splenic B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20077527     DOI: 10.1002/path.2665

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  16 in total

1.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

2.  BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.

Authors:  Qingguo Yan; Yuanxue Huang; A James Watkins; Sylvia Kocialkowski; Naiyan Zeng; Rifat A Hamoudi; Peter G Isaacson; Laurence de Leval; Andrew Wotherspoon; Ming-Qing Du
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

3.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Authors:  A Clipson; M Wang; L de Leval; M Ashton-Key; A Wotherspoon; G Vassiliou; N Bolli; C Grove; S Moody; L Escudero-Ibarz; G Gundem; K Brugger; X Xue; E Mi; A Bench; M Scott; H Liu; G Follows; E F Robles; J A Martinez-Climent; D Oscier; A J Watkins; M-Q Du
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

4.  Exon 1 disruption alters tissue-specific expression of mouse p53 and results in selective development of B cell lymphomas.

Authors:  Y Jeffrey Chiang; Michael J Difilippantonio; Lino Tessarollo; Herbert C Morse; Richard J Hodes
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

5.  An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma.

Authors:  A James Watkins; Rifat A Hamoudi; Naiyan Zeng; Qingguo Yan; Yuanxue Huang; Hongxiang Liu; Jianzhong Zhang; Esteban Braggio; Rafael Fonseca; Laurence de Leval; Peter G Isaacson; Andrew Wotherspoon; Ellen D McPhail; Ahmet Dogan; Ming-Qing Du
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

6.  Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.

Authors:  Mark J Kiel; Thirunavukkarasu Velusamy; Bryan L Betz; Lili Zhao; Helmut G Weigelin; Mark Y Chiang; David R Huebner-Chan; Nathanael G Bailey; David T Yang; Govind Bhagat; Roberto N Miranda; David W Bahler; L Jeffrey Medeiros; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

7.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.

Authors:  Davide Rossi; Vladimir Trifonov; Marco Fangazio; Alessio Bruscaggin; Silvia Rasi; Valeria Spina; Sara Monti; Tiziana Vaisitti; Francesca Arruga; Rosella Famà; Carmela Ciardullo; Mariangela Greco; Stefania Cresta; Daniela Piranda; Antony Holmes; Giulia Fabbri; Monica Messina; Andrea Rinaldi; Jiguang Wang; Claudio Agostinelli; Pier Paolo Piccaluga; Marco Lucioni; Fabrizio Tabbò; Roberto Serra; Silvia Franceschetti; Clara Deambrogi; Giulia Daniele; Valter Gattei; Roberto Marasca; Fabio Facchetti; Luca Arcaini; Giorgio Inghirami; Francesco Bertoni; Stefano A Pileri; Silvia Deaglio; Robin Foà; Riccardo Dalla-Favera; Laura Pasqualucci; Raul Rabadan; Gianluca Gaidano
Journal:  J Exp Med       Date:  2012-08-13       Impact factor: 14.307

8.  Molecular characterization of the region 7q22.1 in splenic marginal zone lymphomas.

Authors:  Cristina Robledo; Juan L García; Rocío Benito; Teresa Flores; Manuela Mollejo; José Ángel Martínez-Climent; Eva García; Norma C Gutiérrez; Miguel A Piris; Jesús M Hernández
Journal:  PLoS One       Date:  2011-09-21       Impact factor: 3.240

9.  Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma.

Authors:  Antonella Bardi; Francesco Cavazzini; Gian Matteo Rigolin; Elisa Tammiso; Eleonora Volta; Elisa Pezzolo; Luca Formigaro; Olga Sofritti; Giulia Daghia; Cristina Ambrosio; Lara Rizzotto; Awad E Abass; Fiorella D'Auria; Pellegrino Musto; Antonio Cuneo
Journal:  J Biomed Biotechnol       Date:  2011-05-21

10.  CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.

Authors:  Florian Bellutti; Anca-Sarmiza Tigan; Sofie Nebenfuehr; Marlies Dolezal; Markus Zojer; Reinhard Grausenburger; Svenja Hartenberger; Sebastian Kollmann; Eszter Doma; Michaela Prchal-Murphy; Iris Z Uras; Alexander Höllein; Donna S Neuberg; Benjamin L Ebert; Anna Ringler; Andre C Mueller; Joanna I Loizou; Philip W Hinds; Claus Vogl; Gerwin Heller; Stefan Kubicek; Johannes Zuber; Marcos Malumbres; Matthias Farlik; Andreas Villunger; Karoline Kollmann; Veronika Sexl
Journal:  Cancer Discov       Date:  2018-06-13       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.